Nicolas Chapuis

The share of this author’s assessed papers carrying a ⚑ flag. A concentration is a prompt for expert review — never, on its own, a determination about the person.

Collaborators, sized by shared output and coloured by their own reproducibility (green = high, red = low). Click a node to open their card. A pattern is a prompt for review, never a determination.

How this author’s assessed papers reproduced — the outcome of reproduction attempts, not a judgement of the person. Coverage is partial and grows over time.

Assessed papers (1)

• Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia.⚑
  2025 L1 32/100 ⚑

1 assessed by us (0 reproduced) · 170 not yet assessed — every PubMed paper on record, linked below.

• High frequency of <scp>CD95</scp> ⁺ / <scp>CD45RA</scp> ⁻ regulatory T cells defines an immunosuppressive profile associated with <scp>MDS</scp> progression ↗

  British Journal of Haematology · 2026 · PMID 42080308
  not yet assessed
• High Proportion of <scp>PNH</scp> Type <scp>II</scp> Neutrophils Is Associated With Thrombosis in Patients Displaying a <scp>PNH</scp> Clone ≥ 1% ↗

  American Journal of Hematology · 2026 · PMID 42400241
  not yet assessed
• Multicenter Flow Cytometry For Acute Myeloid Leukemia Measurable Residual Disease With LAIP/DfN And CD34&lt;sup&gt;+&lt;/sup&gt;CD38&lt;sup&gt;-&lt;/sup&gt; Leukemic Stem Cell-Enriched Populations ↗

  Journal of Visualized Experiments · 2026
  not yet assessed
• IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score ↗

  Blood · 2025 · PMID 40561337
  not yet assessed
• Molecular profiling and risk stratification in solitary bone plasmacytoma ↗

  Leukemia · 2025 · PMID 40954216
  not yet assessed
• Boosting large scale capacitive harvesting of osmotic power by dynamic matching of ion exchange kinetics ↗

  Sustainable Energy & Fuels · 2025
  not yet assessed
• Development of Machine‐Assisted, Human‐Centred Bone Marrow Cell Classification: Feasibility Analysis in Patients With Myelodysplastic Syndromes ↗

  eJHaem · 2025 · PMID 41409738
  not yet assessed
• Pro-inflammatory role of granzyme K producing bystander CD8 ⁺ T cells in acute myeloid leukemia ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2025
  not yet assessed
• RAPID FIRE SESSION 01 ↗

  Leukemia Research · 2025
  not yet assessed
• MDS BIOLOGY AND PATHOGENESIS - IMMUNE DEREGULATION / INFLAMMATION ↗

  Leukemia Research · 2025
  not yet assessed
• Integrated analysis of post-transcriptional regulations reveals insights into acute myeloid leukemia⚑

  Communications Biology · 2025 · PMID 41407883
  L1 32/100 ⚑
• Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment ↗

  American Journal of Hematology · 2024 · PMID 38899566
  not yet assessed
• Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation ↗

  Nature Communications · 2024 · PMID 38589367
  not yet assessed
• Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium ↗

  HemaSphere · 2024 · PMID 38756352
  not yet assessed
• Flow cytometric analysis of erythroid precursors and mutational signatures of lower risk myelodysplastic syndromes identify responders to erythroid stimulating agents ↗

  Blood Cancer Journal · 2024 · PMID 39112451
  not yet assessed
• Along with PaO2/FiO2 ratio and lymphopenia, low HLA-DR monocytes are the only additional parameter that independently predicts the clinical course of undifferentiated SARS-CoV-2 patients in emergency departments ↗

  Journal of Leukocyte Biology · 2024 · PMID 38366559
  not yet assessed
• Multicenter inter‐laboratory quality control of monocyte <scp>HLA</scp>‐<scp>DR</scp> expression by flow cytometry ↗

  Cytometry Part B Clinical Cytometry · 2024 · PMID 38924678
  not yet assessed
• Loss of hematopoietic progenitors heterogeneity is an adverse prognostic factor in lower-risk myelodysplastic neoplasms ↗

  Leukemia · 2024 · PMID 38575672
  not yet assessed
• Clinical and biological characteristics of patients presenting with carcinocythaemia: A retrospective, multicentre study by the French‐speaking Cellular Hematology Group (<scp>GFHC</scp>) ↗

  British Journal of Haematology · 2024 · PMID 39183701
  not yet assessed
• Flow MRD Monitoring Combining Laip/Dfn and CD34+CD38- LSCs Is a Strong Predictor of Outcome in Adult AML Independently of the ELN-2022 Risk: First Results from the Multicentric Acute Leukemia French Intergroup MRD Flow Network ↗

  Blood · 2024
  not yet assessed
• White blood cells scattergram as a valuable tool for <scp>COVID</scp>‐19 screening: A multicentric study ↗

  International Journal of Laboratory Hematology · 2024 · PMID 38439664
  not yet assessed
• High Proportion of PNH Type II Neutrophils, I.e. Relative Percentage ≥3%, Is Associated with Thrombosis in Patients Displaying a PNH Clone &amp;gt;1%: Evidence from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study ↗

  Blood · 2024
  not yet assessed
• Dihydroartemisinin-induced ferroptosis in acute myeloid leukemia: links to iron metabolism and metallothionein ↗

  Cell Death Discovery · 2023 · PMID 36928207
  not yet assessed
• Artificial intelligence to empower diagnosis of myelodysplastic syndromes by multiparametric flow cytometry ↗

  Haematologica · 2023 · PMID 36924240
  not yet assessed
• Neutralizing Antibody Levels as a Correlate of Protection Against <scp>SARS‐CoV</scp>‐2 Infection: A Modeling Analysis ↗

  Clinical Pharmacology & Therapeutics · 2023 · PMID 37795693
  not yet assessed
• Waste heat recovery using thermally responsive ionic liquids through TiO ₂ nanopore and macroscopic membranes ↗

  Energy & Environmental Science · 2023
  not yet assessed
• Enhanced fetal hematopoiesis in response to symptomatic SARS-CoV-2 infection during pregnancy ↗

  Communications Medicine · 2023 · PMID 38082066
  not yet assessed
• Physiopathologie des syndromes myélodysplasiques ↗

  Bulletin du Cancer · 2023 · PMID 37423830
  not yet assessed
• Modelling the association between neutralizing antibody levels and SARS-CoV-2 viral dynamics : implications to define correlates of protection against infection ↗

  medRxiv · 2023
  not yet assessed
• Impact of Mutational Burden and IPSS-M on Response to ESAs in Lower Risk Myelodysplastic Neoplasms ↗

  Blood · 2023
  not yet assessed
• Subcutaneous azacitidine maintenance in transplantineligible patients with acute myeloid leukemia: a single-center retrospective study ↗

  Haematologica · 2023 · PMID 36994502
  not yet assessed
• Supplementary Figure Legend, Table 1 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗

  2023
  not yet assessed
• Supplementary Figures 1 - 4 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗

  2023
  not yet assessed
• Data from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗

  2023
  not yet assessed
• Data from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗

  2023
  not yet assessed
• Supplementary Figure Legend, Table 1 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗

  2023
  not yet assessed
• Supplementary Figures 1 - 4 from Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗

  2023
  not yet assessed
• Topic: AS04-MDS Biology and Pathogenesis/AS04e-Spliceosome machinery: DNA REPLICATION STRESS DUE TO LOSS OF R-LOOPS IN MYELODYSPLASTIC SYNDROMES WITH SF3B1 MUTATION ↗

  Leukemia Research · 2023
  not yet assessed
• Topic: AS01-Diagnosis/AS01b-Flow cytometry: COMMITTED AND IMMATURE ERYTHROID PROGENITORS ARE DIFFERENTLY DISTRIBUTED IN LOWER RISK MYELODYSPLASTIC SYNDROMES ACCORDING TO WHO CATEGORY AND CORRELATE WITH RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS ↗

  Leukemia Research · 2023
  not yet assessed
• S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES ↗

  HemaSphere · 2023
  not yet assessed
• S169: MODULATION OF THE IMMUNE LANDSCAPE IN LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH IMETELSTAT-INDUCED TRANSFUSION INDEPENDENCY ↗

  HemaSphere · 2023
  not yet assessed
• New avenues for blue energy and waste heat harvesting

  theses.fr (ABES) · 2023
  not yet assessed
• Nouvelles approches pour l'énergie osmotique et les chaleurs fatales

  HAL (Le Centre pour la Communication Scientifique Directe) · 2023
  not yet assessed
• Nouvelles approches pour l'énergie osmotique et les chaleurs fatales ↗

  2023
  not yet assessed
• Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues ↗

  Cytometry Part B Clinical Cytometry · 2022 · PMID 36537621
  not yet assessed
• Optical genome mapping refines cytogenetic diagnostics, prognostic stratification and provides new molecular insights in adult MDS/AML patients ↗

  Blood Cancer Journal · 2022 · PMID 36055992
  not yet assessed
• Dynamics of circulating calprotectin accurately predict the outcome of moderate COVID-19 patients ↗

  EBioMedicine · 2022 · PMID 35644124
  not yet assessed
• RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia ↗

  Leukemia · 2022 · PMID 35354920
  not yet assessed
• Diagnosis of acute promyelocytic leukemia based on routine biological parameters using machine learning ↗

  Haematologica · 2022 · PMID 35199507
  not yet assessed
• Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients ↗

  Journal of Clinical Medicine · 2022 · PMID 36233427
  not yet assessed
• Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications ↗

  Diagnostics · 2022 · PMID 35885563
  not yet assessed
• AML MRD By Multiparameter Flow Cytometry Using Laip/Dfn and LSC: Methodological Aspects in a Multicentric Study of the French-Flow MRD AML ALFA Network ↗

  Blood · 2022
  not yet assessed
• Methaemoglobinaemia and haemolysis after rasburicase administration in a patient with G6PD deficiency ↗

  BMJ Case Reports · 2022 · PMID 36198433
  not yet assessed
• Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis ↗

  Acta Oncologica · 2022 · PMID 35243961
  not yet assessed
• Effets de la dihydroartémisinine sur la régulation du métabolisme du fer et de la ferroptose dans les leucémies aiguës myéloïdes ↗

  2022
  not yet assessed
• DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with <i>SF3B1</i> Mutation ↗

  Blood · 2022
  not yet assessed
• Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study ↗

  Blood · 2022
  not yet assessed
• Etoposide-containing regimens for the treatment of critically ill patients with hematological malignancy-related hemophagocytic lymphohistiocytosis ↗

  Figshare · 2022
  not yet assessed
• COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects ↗

  Angiogenesis · 2021 · PMID 34184164
  not yet assessed
• APR-246 induces early cell death by ferroptosis in acute myeloid leukemia ↗

  Haematologica · 2021 · PMID 33406814
  not yet assessed
• Oxidative Stress and Inflammatory Biomarkers for the Prediction of Severity and ICU Admission in Unselected Patients Hospitalized with COVID-19 ↗

  International Journal of Molecular Sciences · 2021 · PMID 34299080
  not yet assessed
• Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European <scp>LeukemiaNet</scp> ↗

  Cytometry Part B Clinical Cytometry · 2021 · PMID 34894176
  not yet assessed
• Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European <scp>LeukemiaNet</scp> International <scp>MDS‐Flow</scp> Cytometry Working Group ↗

  Cytometry Part B Clinical Cytometry · 2021 · PMID 34897979
  not yet assessed
• Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis ↗

  Intensive Care Medicine · 2021 · PMID 33688993
  not yet assessed
• ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data ↗

  eLife · 2021 · PMID 33929322
  not yet assessed
• Asciminib and ponatinib combination in Philadelphia chromosome-positive acute lymphoblastic leukemia ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2021 · PMID 34405773
  not yet assessed
• Venetoclax combination therapy induces deep AML remission with eradication of leukemic stem cells and remodeling of clonal haematopoiesis ↗

  Blood Cancer Journal · 2021 · PMID 33741892
  not yet assessed
• Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy ↗

  Cancers · 2021 · PMID 34503133
  not yet assessed
• Ferroptose et cancer ↗

  médecine/sciences · 2021 · PMID 34491180
  not yet assessed
• Author response: ImmunoCluster provides a computational framework for the nonspecialist to profile high-dimensional cytometry data ↗

  2021
  not yet assessed
• PREDICTIVE VALUE OF FDG PET/CT IN PATIENTS WITH RELAPSE/REFRACTORY MULTIPLE MYELOMA BEFORE TREATMENT WITH ANTI‐CD38 IMMUNOTHERAPY ↗

  Hematological Oncology · 2021
  not yet assessed
• Spectre des maladies auto-immunes ou inflammatoires associées à une prolifération T clonale de signification indéterminée ↗

  La Revue de Médecine Interne · 2021
  not yet assessed
• Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 ↗

  Cell · 2020 · PMID 32810439
  not yet assessed
• Pairing MCL‐1 inhibition with venetoclax improves therapeutic efficiency of BH3‐mimetics in AML ↗

  European Journal Of Haematology · 2020 · PMID 32659848
  not yet assessed
• From Iron Chelation to Overload as a Therapeutic Strategy to Induce Ferroptosis in Leukemic Cells ↗

  Frontiers in Oncology · 2020 · PMID 33042852
  not yet assessed
• Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia ↗

  Oncogenesis · 2020 · PMID 33093450
  not yet assessed
• Multicentric MFI30 study: Standardization of flow cytometry analysis of CD30 expression in non‐Hodgkin lymphoma ↗

  Cytometry Part B Clinical Cytometry · 2020 · PMID 32803917
  not yet assessed
• EU-China relations in the time of COVID-19 ↗

  Asia Europe Journal · 2020 · PMID 32837471
  not yet assessed
• Immunocluster: A Computational Tool to Explore the Immune Profile and Cellular Heterogeneity of Hematological Diseases Using Liquid and Imaging Mass, and Flow Cytometry Data ↗

  Blood · 2020
  not yet assessed
• A meal served cold ↗

  British Journal of Haematology · 2020 · PMID 32239505
  not yet assessed
• Improvement of therapy-induced myelodysplastic syndrome by infusion of autologous CD34-positive hematopoietic progenitor cells without chemotherapy ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2020 · PMID 32856491
  not yet assessed
• ImmunoCluster: A computational framework for the non-specialist to profile cellular heterogeneity in cytometry datasets ↗

  bioRxiv (Cold Spring Harbor Laboratory) · 2020
  not yet assessed
• Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia ↗

  Frontiers in Oncology · 2019 · PMID 31192118
  not yet assessed
• Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1‐tube panel strategy for diagnosis and prognosis of patients with MDS ↗

  Cytometry Part B Clinical Cytometry · 2019 · PMID 31498561
  not yet assessed
• The fraction of CD117/c‐KIT‐expressing erythroid precursors predicts ESA response in low‐risk myelodysplastic syndromes ↗

  Cytometry Part B Clinical Cytometry · 2019 · PMID 30963682
  not yet assessed
• Lymphocyte Immunophenotyping and CD4/CD8 Ratio in Cerebrospinal Fluid for the Diagnosis of Sarcoidosis-related Uveitis ↗

  Ocular Immunology and Inflammation · 2019 · PMID 31671003
  not yet assessed
• Paraneoplastic Hyperleukocytosis Mimicking Hematologic Malignancy Revealing a Localized Lung Cancer ↗

  The Annals of Thoracic Surgery · 2019 · PMID 31408646
  not yet assessed
• Too big for flow ↗

  Blood · 2019 · PMID 31395585
  not yet assessed
• MULTICENTRIC MFI30 STUDY: STANDARDIZATION OF CD30 EXPRESSION BY FLOW CYTOMETRY IN NON‐HODGKIN LYMPHOMA ↗

  Hematological Oncology · 2019
  not yet assessed
• Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models ↗

  Blood · 2019
  not yet assessed
• Multicentric Standardized Flow Cytometry Routine Assessment of Patients With Sepsis to Predict Clinical Worsening ↗

  CHEST Journal · 2018 · PMID 29705219
  not yet assessed
• A miR-150/TET3 pathway regulates the generation of mouse and human non-classical monocyte subset ↗

  Nature Communications · 2018 · PMID 30575719
  not yet assessed
• Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis ↗

  Blood Cancer Journal · 2018 · PMID 30429467
  not yet assessed
• Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes ↗

  Haematologica · 2018 · PMID 30287621
  not yet assessed
• <scp>CD</scp>13 expression in B cell malignancies is a hallmark of plasmacytic differentiation ↗

  British Journal of Haematology · 2018 · PMID 30198568
  not yet assessed
• Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on CD34+ cells ↗

  Leukemia Research · 2018 · PMID 30025279
  not yet assessed
• T-cell large granular lymphocyte leukemia transfomation into aggressive T-cell lymphoma: a report of two cases with molecular characterization ↗

  Haematologica · 2018 · PMID 30573508
  not yet assessed
• A pernicious mean corpuscular volume ↗

  Blood · 2018 · PMID 29371209
  not yet assessed
• Multicentric MFI30 Study: Standardization of CD30 Expression By Flow Cytometry in Non-Hodgkin Lymphoma ↗

  Blood · 2018
  not yet assessed
• Dyserythropoiesis Evaluated by Red Score and Hepcidin/Ferritin Levels Predicts Response to Erythropoietin in Lower Risk Myelodysplastic Syndromes ↗

  SSRN Electronic Journal · 2018
  not yet assessed
• Diplomatie française ↗

  Odile Jacob eBooks · 2018
  not yet assessed
• High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells ↗

  Leukemia · 2017 · PMID 28280275
  not yet assessed
• Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling ↗

  Leukemia · 2017 · PMID 28972593
  not yet assessed
• Évaluation de l’intérêt de l’étude du liquide céphalorachidien sur Transfix® au cours des uvéites postérieures et/ou intermédiaires ↗

  La Revue de Médecine Interne · 2017
  not yet assessed
• Lenalidomide-Mediated Erythroid Improvement in Non-Del(5q) Myelodysplastic Syndromes Is Associated with Bone Marrow Immuno-Remodeling ↗

  Blood · 2017
  not yet assessed
• Dual mTORC1/2 inhibition induces anti-proliferative effect in NF1-associated plexiform neurofibroma and malignant peripheral nerve sheath tumor cells ↗

  Oncotarget · 2016 · PMID 26840085
  not yet assessed
• Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia ↗

  Scientific Reports · 2016 · PMID 27759041
  not yet assessed
• Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes ↗

  Blood · 2016 · PMID 27856460
  not yet assessed
• Immature/total granulocyte ratio improves early prediction of neurological outcome after out-of-hospital cardiac arrest: the MyeloScore study ↗

  Annals of Intensive Care · 2016 · PMID 27422256
  not yet assessed
• APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis ↗

  Oncotarget · 2016 · PMID 26910909
  not yet assessed
• Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients ↗

  Pharmacological Research · 2016 · PMID 27378568
  not yet assessed
• Plasma cell leukemia revealing a G6PD deficiency ↗

  Blood · 2016 · PMID 28034875
  not yet assessed
• Architectural and Functional Heterogeneity of Hematopoietic Stem/Progenitor Cells in Non-Del(5q) Myelodysplastic Syndromes ↗

  Blood · 2016
  not yet assessed
• APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesis , on behalf of the Groupe Francophone des Myélodysplasies

  HAL (Le Centre pour la Communication Scientifique Directe) · 2016
  not yet assessed
• Clonal B-Cell Lymphocytosis with Marginal Zone Features and Splenic Marginal Zone Lymphoma Share a Similar Cytogenetic and Mutational Profile ↗

  Blood · 2016
  not yet assessed
• Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition ↗

  Blood · 2015 · PMID 26186940
  not yet assessed
• Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma ↗

  Targeted Oncology · 2015 · PMID 26208946
  not yet assessed
• Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms ↗

  Haematologica · 2015 · PMID 25637056
  not yet assessed
• Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters ↗

  Cancer Chemotherapy and Pharmacology · 2015 · PMID 26420236
  not yet assessed
• Frontline Clofarabine and Cytarabine combination for plasmocytoid blastic dendritic cell neoplasm ↗

  Cancer Research Frontiers · 2015
  not yet assessed
• 104 APG101 (SOLUBLE CD95-FC) IMPROVES BFU-E GROWTH IN LOWER RISK MYELODYSPLASTIC SYNDROME WITH COLLAPSED ERYTHROPOIESIS: A PRECLINICAL STUDY ↗

  Leukemia Research · 2015
  not yet assessed
• Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors. ↗

  Journal of Clinical Oncology · 2015
  not yet assessed
• Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy ↗

  Cytometry Part B Clinical Cytometry · 2014 · PMID 25399680
  not yet assessed
• Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy ↗

  Cytometry Part B Clinical Cytometry · 2014 · PMID 25349085
  not yet assessed
• Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia ↗

  Blood · 2013 · PMID 24014241
  not yet assessed
• Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes ↗

  Leukemia · 2013 · PMID 23765225
  not yet assessed
• A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse ↗

  Leukemia · 2013 · PMID 23321953
  not yet assessed
• P-071 Flow cytometric detection of dyserythropoiesis is a sensitive and powerful tool for myelodysplastic syndrome diagnosis ↗

  Leukemia Research · 2013
  not yet assessed
• " Diplomatie 2.0 " : la révolution numérique au service de la diplomatie française et de la modernisation de l'action publique

  HAL (Le Centre pour la Communication Scientifique Directe) · 2013
  not yet assessed
• PI3K and mTOR Signaling Pathways in Cancer: New Data on Targeted Therapies ↗

  Current Oncology Reports · 2012 · PMID 22350330
  not yet assessed
• A dramatic fetal outcome following transplacental transfer of dasatinib ↗

  Anti-Cancer Drugs · 2012 · PMID 22421368
  not yet assessed
• Sustained Leukemia-Free State and Molecular Response to Sorafenib in a Patient With Chronic Myelomonocytic Leukemia in Transformation Driven by Homozygous FLT3-ITD Malignant Hematopoiesis ↗

  Clinical Lymphoma Myeloma & Leukemia · 2012 · PMID 23246161
  not yet assessed
• Targeted Therapy in CMML: Complete Molecular Response to Sorafenib in a Patient with a FLT3-ITD Malignant Hematopoiesis ↗

  Blood · 2012
  not yet assessed
• Témoignage - Du secret des chancelleries à l’agora des réseaux : les nouveaux enjeux de l’écriture diplomatique ↗

  Cairn.info · 2012
  not yet assessed
• High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study ↗

  Haematologica · 2011 · PMID 21933861
  not yet assessed
• The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia ↗

  Leukemia · 2011 · PMID 22143671
  not yet assessed
• LKB1/AMPK/mTOR signaling pathway in hematological malignancies: From metabolism to cancer cell biology ↗

  Cell Cycle · 2011 · PMID 21572254
  not yet assessed
• Salvage therapy of Autoimmune Thrombocytopenic Purpura revealing non‐Hodgkin Lymphoma by the thrombopoietin receptor agonist romiplostim ↗

  British Journal of Haematology · 2011 · PMID 21848881
  not yet assessed
• The eukaryotic Initiating Factor 4E protein is overexpressed, but its level has no prognostic impact in acute myeloid leukaemia ↗

  British Journal of Haematology · 2011 · PMID 21995271
  not yet assessed
• RAD001: A Clinico-Biological Phase I GOELAMS trial of Everolimus Association with High Dose Chemotherapy in Late Relapsing AML Patients Under 65 Years of Age ↗

  Blood · 2011
  not yet assessed
• Dérégulation des voies de signalisation P13K/Akt et mTOR dans les Leucémies Aigües Myéloïdes

  2011
  not yet assessed
• The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation ↗

  Blood · 2010 · PMID 20668229
  not yet assessed
• Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia ↗

  Clinical Cancer Research · 2010 · PMID 20884625
  not yet assessed
• Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies ↗

  Leukemia · 2010 · PMID 20703258
  not yet assessed
• IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia ↗

  Blood · 2010 · PMID 20671123
  not yet assessed
• Insulin Receptor A and IGF-1R in AML – Letter ↗

  Cancer Research · 2010 · PMID 20699367
  not yet assessed
• Prognostic Impact of the Amount of CD34+ CD38- CD123+ Cells at Diagnosis In Acute Myeloid Leukemia: a Study From the GOELAMS ↗

  Blood · 2010
  not yet assessed
• Targeted inhibition of mtor by azd8055 blocks protein translation and has anti-leukemic activity in acute myeloid leukemia

  HAL (Le Centre pour la Communication Scientifique Directe) · 2010
  not yet assessed
• Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia ↗

  Haematologica · 2009 · PMID 19951971
  not yet assessed
• Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia ↗

  Blood · 2009 · PMID 19458359
  not yet assessed
• Autocrine IGF-1/IGF-1R signaling is responsible for constitutive PI3K/Akt activation in acute myeloid leukemia: therapeutic value of neutralizing anti-IGF-1R antibody ↗

  Haematologica · 2009 · PMID 20007139
  not yet assessed
• Targeting translation in acute myeloid leukemia: A new paradigm for therapy? ↗

  Cell Cycle · 2009 · PMID 19934662
  not yet assessed
• The PI3K/mTOR Inhibitor NVP-BEZ235 Is a Promising Pre-Clinical Candidate for Therapeutic Intervention in Acute Myeloid Leukemia. ↗

  Blood · 2009
  not yet assessed
• IκB Kinase Overcomes PI3K to Control FoxO3a Subcellular Localization in Acute Myeloid Leukemia. ↗

  Blood · 2009
  not yet assessed
• PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML ↗

  Leukemia · 2008 · PMID 18548104
  not yet assessed
• Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy ↗

  Leukemia & lymphoma/Leukemia and lymphoma · 2008 · PMID 18720213
  not yet assessed
• Autocrine IGF-1/IGF-1R Signaling Is Responsible for PI3K/Akt Constitutive Activation in Acute Myeloid Leukemia. ↗

  Blood · 2008
  not yet assessed
• Protein Synthesis Escapes mTORC1 Control and Constitutes a Promising Therapeutic Target in Acute Myeloid Leukemia. ↗

  Blood · 2008
  not yet assessed
• mTORC1 Activity Is Independent of PI3K/Akt but Controlled by AMPK in Acute Myeloid Leukemia. ↗

  Blood · 2008
  not yet assessed
• Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways ↗

  Blood · 2007 · PMID 17878402
  not yet assessed
• Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients ↗

  Blood · 2007 · PMID 17426258
  not yet assessed
• Molecular characterization of a novel mutation in the factor XIII A subunit gene associated with a severe defect and an adulthood diagnosis ↗

  Haemophilia · 2007 · PMID 17286781
  not yet assessed
• PI-103, a Dual Inhibitor of Class I Phosphatidylinositide 3-Kinase and mTOR, Has Anti-Leukemic Activity in Acute Myeloid Leukemia. ↗

  Blood · 2007
  not yet assessed
• Rational for Specific Inhibition of Both PI3K/AKT and mTORC1 Activities in Acute Myelogenous Leukaemia. ↗

  Blood · 2006
  not yet assessed
• François Jullien, La Grande Image n'a pas de forme ou du non-objet par la peinture, « L'ordre philosophique », 2003

  Persée (Ministère de lEnseignement supérieur et de la Recherche) · 2004
  not yet assessed
• Morale collective et éthique privée dans la poésie chinoise ↗

  Commentaire · 2002
  not yet assessed
• [Flexible choledochoscopy: two years experience]. ↗

  PubMed · 1993 · PMID 8226089
  not yet assessed
• [Simultaneous proximal and distal revascularization for arterial obstruction of the leg at two sites. Indications, techniques and results]. ↗

  PubMed · 1993 · PMID 8376149
  not yet assessed
• [In situ venous grafts. Indications, technique and results. Prospective study of 26 consecutive cases]. ↗

  PubMed · 1993 · PMID 8376150
  not yet assessed
• Sombres nuées ↗

  World Literature Today · 1992
  not yet assessed
• Le jardin du repos ↗

  World Literature Today · 1979
  not yet assessed